We believe patients deserve better
We are deeply committed to making cell therapies broadly accessible to patients with autoimmune disease and cancer.
Artiva Biotherapeutics: Unlocking NK Cell Therapy for Autoimmune Disease and Cancer
The past decade has seen meaningful advances in cell therapy, with dramatic rates of clinical response in hematological malignancies and autoimmune disease. However, these therapies have been accompanied by severe and potentially life-threatening toxicities, and patient access is limited by complex, time-consuming, and costly patient-specific manufacturing. Cell therapy today is for the few, but we can do more.
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). AlloNK is currently in clinical trials for treatment of systemic lupus erythematosus (SLE) in patients with or without lupus nephritis and in an investigator-initiated basket trial in multiple autoimmune indications. In addition, AlloNK is being evaluated for the treatment of non-Hodgkin lymphoma, as well as in combination with Affimed’s innate cell engager acimtamig for the treatment of patients with relapsed/refractory CD30-positive lymphomas.